Eli Lilly and MacroGenics announced that they have suspended phase III trials of Protégé, a drug designed to address the autoimmune component in people with Type 1 diabetes, according to an article form InPharma.
The companies pulled the plug in the drug because it did not meet its primary goal. The companies said that there were no unanticipated safety issues, but that safety monitoring among trial participants is warranted.
Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).
See our range of kitbags
